Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Superpotent topical corticosteroid

Halobetasol Propionate

BRYHALI

Dosage form
Tablet
Available strengths
0.01% w/w (0.1 mg halobetasol per gram)
Drug class
Superpotent topical corticosteroid
Common brand
BRYHALI

Clinical overview. Halobetasol propionate (BRYHALI) is a superpotent topical corticosteroid lotion used for plaque psoriasis and other corticosteroid-responsive skin conditions. Because of its high potency, use is limited to short courses on limited body-surface areas to reduce the risk of skin thinning and adrenal suppression.

Indication

Common therapeutic uses

  • Used to treat corticosteroid-responsive skin conditions (dermatoses).
  • Used for the topical treatment of plaque psoriasis affecting a limited portion of the body surface area, excluding the face, scalp, palms, soles, armpits, and skin-fold areas; safety and efficacy have not been established for more extensive disease.

Pregnancy

Risk assessment and monitoring considerations

  • There are no adequate human data on use in pregnant women, so use in pregnancy is not recommended; treatment should be discontinued if the patient becomes pregnant.
  • In animal studies, halobetasol propionate caused fetal malformations, including cleft palate, and was embryotoxic at oral and topical doses well above typical human topical exposure.

Breastfeeding

Infant exposure considerations

  • There are no data on whether halobetasol propionate passes into human milk or affects the nursing infant or milk supply.
  • Because systemically absorbed corticosteroids can appear in breast milk, breastfeeding women should avoid applying the lotion directly to the nipple or areola to prevent direct infant exposure, and should discuss the benefits and risks with their doctor.

Geriatrics

Dosing and tolerability considerations

  • Only a limited number of patients aged 65 and older were treated with BRYHALI in clinical trials, so safety and effectiveness have not been firmly established in this age group.

Pediatrics

Use in children and adolescents

  • Safety and effectiveness have not been evaluated in patients under 18 years of age, and BRYHALI should not be used in children.
  • Because children have a larger skin-surface-to-body-mass ratio than adults, they are at greater risk of HPA-axis suppression, Cushing's syndrome, and adrenal insufficiency with topical corticosteroid use.

Dosage & Administration

Practical dosing and administration

  • Apply a thin layer once daily to the affected areas only, rubbing in gently; if bathing or showering beforehand, allow the skin to dry first.
  • Total use should not exceed approximately 50 g per week, and treatment should not be used continuously for more than 8 weeks.
  • Do not use with occlusive dressings unless specifically directed by a physician.
  • Should not be applied to the face, scalp, groin, or armpits, and should be kept away from the eyes, nose, mouth, and other mucous membranes.

Common side effects

Frequently reported tolerability concerns

  • Upper respiratory tract infection was reported somewhat more often than with the inactive lotion base.
  • Application site reactions such as mild burning, stinging, itching, dryness, or discoloration may occur.
  • Cough may occur.
  • Mildly elevated blood pressure was noted more often than with the inactive base in trials.
  • Gastroenteritis was reported more often than with the inactive base.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Suppression of the body's own adrenal hormone production (HPA-axis suppression) may occur, especially with prolonged use, use over large areas, or use under occlusion, and can lead to glucocorticoid insufficiency after stopping treatment.
  • Cushing's syndrome, high blood sugar, and glucose in the urine can occur with significant systemic absorption.
  • Skin thinning (atrophy), stretch marks (striae), and visible blood vessels can occur, especially with prolonged use, and some changes may be permanent.
  • Application-site allergic contact dermatitis or skin infection can occur.
  • Increased risk of cataracts or glaucoma has been reported with topical corticosteroid use, particularly with use near the eyes.
  • Seek medical attention for vision changes, signs of infection at the application site, or symptoms suggesting adrenal problems such as unusual fatigue, weight change, or dizziness.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with hepatic impairment, since corticosteroids undergo liver metabolism.
  • Use with caution in patients with stasis dermatitis or other skin conditions involving impaired circulation.
  • Use with caution in patients who are hypersensitive to other topical products or who have glaucoma.
  • Evaluate periodically for HPA-axis suppression in patients receiving large doses over large surface areas or for prolonged periods.
  • If a skin infection is present, an appropriate antimicrobial should be used concurrently, and BRYHALI discontinued if a favorable response is not seen promptly.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients hypersensitive to halobetasol propionate or to any ingredient in the formulation.
  • Contraindicated in patients hypersensitive to other corticosteroids.
  • Contraindicated in viral skin infections including herpes simplex, vaccinia, and varicella (chickenpox).
  • Contraindicated in untreated bacterial, tubercular, or fungal skin infections.

Drug interactions

Clinically relevant combinations

  • No formal drug-drug interaction studies have been conducted with BRYHALI.
  • Use of more than one corticosteroid-containing product at the same time can increase total systemic corticosteroid exposure and the risk of systemic side effects.

Food interactions

Meal-related administration

  • Not applicable; this is a topical lotion applied to the skin and is not taken by mouth, so food does not affect its action.

Time of administration

Practical scheduling

  • Apply once daily to affected skin areas only, at a consistent time each day; treatment beyond 8 weeks without reassessment is not recommended.

Storage

Product handling

  • Store at controlled room temperature between 15 and 30 degrees C, and protect from freezing.
  • The in-use period after opening is 8 weeks; discard the tube after this time.

Patient take-away

Key counselling points for a quick closing summary

  • BRYHALI is a strong topical corticosteroid lotion used for plaque psoriasis and other corticosteroid-responsive skin conditions.
  • Apply a thin layer once daily to the affected skin only, and avoid the face, scalp, groin, and armpits.
  • Common effects include mild application-site burning, stinging, itching, or dryness, and occasional cough or upper respiratory symptoms.
  • Contact your doctor if you notice unusual fatigue, vision changes, signs of skin infection, or thinning or stretch marks at the application site, since prolonged use of strong steroids can affect the whole body.
  • Do not use more than about 50 g per week or for longer than 8 weeks without checking with your doctor, and do not cover treated areas with an airtight dressing unless told to.
  • Store at room temperature, protect from freezing, and discard the tube 8 weeks after opening; keep out of reach of children.

References

Source material and product information

  1. Health Canada Product Monograph — Halobetasol Propionate

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.